fluorodopa f 18 has been researched along with Brain Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Degueldre, C; Franck, G; Garraux, G; Laureys, S; Lemaire, C; Peigneux, P; Salmon, E | 1 |
| Imahori, Y; Kawano, H; Misawa, A; Sawada, T; Takeuchi, Y | 1 |
| Kung, HF | 1 |
1 review(s) available for fluorodopa f 18 and Brain Disorders
| Article | Year |
|---|---|
Overview of radiopharmaceuticals for diagnosis of central nervous disorders.
Topics: Brain Diseases; Dihydroxyphenylalanine; Glucose; Humans; Perfusion; Receptors, Dopamine; Technetium; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1991 |
2 other study(ies) available for fluorodopa f 18 and Brain Disorders
| Article | Year |
|---|---|
Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration.
Topics: Aged; Basal Ganglia; Brain Diseases; Cerebral Cortex; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Middle Aged; Nerve Degeneration; Parkinson Disease; Radiopharmaceuticals; Reference Values; Tissue Distribution; Tomography, Emission-Computed | 1999 |
Putaminal necrosis presenting with hemidystonia.
Topics: Antiparkinson Agents; Brain Diseases; Child; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Dystonia; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Levodopa; Magnetic Resonance Imaging; Necrosis; Putamen; Tomography, Emission-Computed; Treatment Outcome | 2000 |